MS multisite study

1 Demographics

Characteristic	N	N = 968¹
Age at the time of first fill in the study period	968
Mean (SD)		50.2 (11.4)
Median (IQR)		51.0 (42.0 - 58.0)
Range		18.0 - 77.0
Gender	968
Female		715 (73.9%)
Male		253 (26.1%)
Site ID	968
Site 1		455 (47.0%)
Site 2		415 (42.9%)
Site 3		50 (5.17%)
Site 4		48 (4.96%)
Insurance	968
Commercial		504 (52.1%)
Medicare		349 (36.1%)
Medicaid		115 (11.9%)
Other		0 (0%)
¹ n (%)

2 Patient reported outcomes (PROs)

A total 6947 PROs were assessed for 968 patients

2.1 Patient-level PROs

2.1.1 Results

Characteristic	N	N = 968¹
Site ID	968
Site 1		455 (47.0%)
Site 2		415 (42.9%)
Site 3		50 (5.17%)
Site 4		48 (4.96%)
Number of PROs	966
Mean (SD)		7.2 (3.7)
Median (IQR)		6.0 (4.0 - 11.0)
Range		1.0 - 15.0
Missing		2
Productivity impacted due to MS (any)	965
No		824 (85.4%)
Yes		141 (14.6%)
Missing		3
Productivity impacted due to MS (total)	965
0		824 (85.4%)
1		81 (8.39%)
2		39 (4.04%)
3		11 (1.14%)
4		7 (0.73%)
5		1 (0.10%)
6		1 (0.10%)
8		1 (0.10%)
Missing		3
MS-related hospitalization (any)	965
No		947 (98.1%)
Yes		18 (1.87%)
Missing		3
MS-related hospitalization (total)	965
0		947 (98.1%)
1		18 (1.87%)
Missing		3
MS-related relapse (any)	965
No		920 (95.3%)
Yes		45 (4.66%)
Missing		3
MS-related relapse (total)	965
0		920 (95.3%)
1		41 (4.25%)
2		2 (0.21%)
3		2 (0.21%)
Missing		3
¹ n (%)

2.1.2 By site

Characteristic	N	Site 1, N = 455¹	Site 2, N = 415¹	Site 3, N = 50¹	Site 4, N = 48¹	Overall, N = 968¹
Number of PROs	966
Mean (SD)		9.9 (3.3)	5.1 (2.0)	3.6 (0.8)	3.0 (1.2)	7.2 (3.7)
Median (IQR)		11.0 (8.0 - 12.0)	5.0 (4.0 - 6.0)	4.0 (3.0 - 4.0)	3.0 (2.0 - 4.0)	6.0 (4.0 - 11.0)
Range		1.0 - 15.0	1.0 - 13.0	1.0 - 5.0	1.0 - 5.0	1.0 - 15.0
Missing		0	0	1	1	2
Productivity impacted due to MS (any)	965
No		450 (98.9%)	290 (69.9%)	38 (77.6%)	46 (100.0%)	824 (85.4%)
Yes		5 (1.10%)	125 (30.1%)	11 (22.4%)	0 (0%)	141 (14.6%)
Missing		0	0	1	2	3
Productivity impacted due to MS (total)	965
0		450 (98.9%)	290 (69.9%)	38 (77.6%)	46 (100.0%)	824 (85.4%)
1		5 (1.10%)	71 (17.1%)	5 (10.2%)	0 (0%)	81 (8.39%)
2		0 (0%)	34 (8.19%)	5 (10.2%)	0 (0%)	39 (4.04%)
3		0 (0%)	10 (2.41%)	1 (2.04%)	0 (0%)	11 (1.14%)
4		0 (0%)	7 (1.69%)	0 (0%)	0 (0%)	7 (0.73%)
5		0 (0%)	1 (0.24%)	0 (0%)	0 (0%)	1 (0.10%)
6		0 (0%)	1 (0.24%)	0 (0%)	0 (0%)	1 (0.10%)
8		0 (0%)	1 (0.24%)	0 (0%)	0 (0%)	1 (0.10%)
Missing		0	0	1	2	3
MS-related hospitalization (any)	965
No		447 (98.2%)	405 (97.6%)	49 (100.0%)	46 (100.0%)	947 (98.1%)
Yes		8 (1.76%)	10 (2.41%)	0 (0%)	0 (0%)	18 (1.87%)
Missing		0	0	1	2	3
MS-related hospitalization (total)	965
0		447 (98.2%)	405 (97.6%)	49 (100.0%)	46 (100.0%)	947 (98.1%)
1		8 (1.76%)	10 (2.41%)	0 (0%)	0 (0%)	18 (1.87%)
Missing		0	0	1	2	3
MS-related relapse (any)	965
No		447 (98.2%)	390 (94.0%)	38 (77.6%)	45 (97.8%)	920 (95.3%)
Yes		8 (1.76%)	25 (6.02%)	11 (22.4%)	1 (2.17%)	45 (4.66%)
Missing		0	0	1	2	3
MS-related relapse (total)	965
0		447 (98.2%)	390 (94.0%)	38 (77.6%)	45 (97.8%)	920 (95.3%)
1		8 (1.76%)	23 (5.54%)	9 (18.4%)	1 (2.17%)	41 (4.25%)
2		0 (0%)	2 (0.48%)	0 (0%)	0 (0%)	2 (0.21%)
3		0 (0%)	0 (0%)	2 (4.08%)	0 (0%)	2 (0.21%)
Missing		0	0	1	2	3
¹ n (%)

2.2 PRO totals

2.2.1 Overall

Reported at the PRO level

Characteristic	N	N = 6947¹
Productivity impacted due to MS	6946
No		6707 (96.6%)
Yes		239 (3.44%)
Missing		1
MS-related hospitalization	6946
No		6928 (99.7%)
Yes		18 (0.26%)
Missing		1
MS-related relapse	6946
No		6895 (99.3%)
Yes		51 (0.73%)
Missing		1
Medication prescribed	6947
Aubagio (teriflunomide)		800 (11.5%)
Avonex (interferon beta-1a)		530 (7.63%)
Betaseron (interferon beta-1b)		144 (2.07%)
Extavia (interferon beta-1b)		23 (0.33%)
Gilenya (fingolimod)		1423 (20.5%)
glatiramer acetate		1882 (27.1%)
Mayzent (siponimod)		41 (0.59%)
Plegridy (pegin-terferon beta-1a)		142 (2.04%)
Rebif (interferon beta-1a)		607 (8.74%)
Tecfidera (dimethyl fumarate)		1313 (18.9%)
Vumerity (diroximol fumarate)		42 (0.60%)
¹ n (%)

2.2.2 By site

Characteristic	N	Site 1, N = 4507¹	Site 2, N = 2123¹	Site 3, N = 176¹	Site 4, N = 141¹	Overall, N = 6947¹
Productivity impacted due to MS	6946
No		4502 (99.9%)	1907 (89.8%)	158 (89.8%)	140 (100.0%)	6707 (96.6%)
Yes		5 (0.11%)	216 (10.2%)	18 (10.2%)	0 (0%)	239 (3.44%)
Missing		0	0	0	1	1
MS-related hospitalization	6946
No		4499 (99.8%)	2113 (99.5%)	176 (100.0%)	140 (100.0%)	6928 (99.7%)
Yes		8 (0.18%)	10 (0.47%)	0 (0%)	0 (0%)	18 (0.26%)
Missing		0	0	0	1	1
MS-related relapse	6946
No		4499 (99.8%)	2096 (98.7%)	161 (91.5%)	139 (99.3%)	6895 (99.3%)
Yes		8 (0.18%)	27 (1.27%)	15 (8.52%)	1 (0.71%)	51 (0.73%)
Missing		0	0	0	1	1
Medication prescribed	6947
Aubagio (teriflunomide)		431 (9.56%)	273 (12.9%)	45 (25.6%)	51 (36.2%)	800 (11.5%)
Avonex (interferon beta-1a)		352 (7.81%)	175 (8.24%)	3 (1.70%)	0 (0%)	530 (7.63%)
Betaseron (interferon beta-1b)		121 (2.68%)	23 (1.08%)	0 (0%)	0 (0%)	144 (2.07%)
Extavia (interferon beta-1b)		23 (0.51%)	0 (0%)	0 (0%)	0 (0%)	23 (0.33%)
Gilenya (fingolimod)		1026 (22.8%)	376 (17.7%)	12 (6.82%)	9 (6.38%)	1423 (20.5%)
glatiramer acetate		954 (21.2%)	833 (39.2%)	56 (31.8%)	39 (27.7%)	1882 (27.1%)
Mayzent (siponimod)		14 (0.31%)	16 (0.75%)	0 (0%)	11 (7.80%)	41 (0.59%)
Plegridy (pegin-terferon beta-1a)		124 (2.75%)	11 (0.52%)	4 (2.27%)	3 (2.13%)	142 (2.04%)
Rebif (interferon beta-1a)		501 (11.1%)	95 (4.47%)	8 (4.55%)	3 (2.13%)	607 (8.74%)
Tecfidera (dimethyl fumarate)		947 (21.0%)	293 (13.8%)	48 (27.3%)	25 (17.7%)	1313 (18.9%)
Vumerity (diroximol fumarate)		14 (0.31%)	28 (1.32%)	0 (0%)	0 (0%)	42 (0.60%)
¹ n (%)

2.3 PROs and medications

2.3.1 By medication (figures)

2.3.2 By medication

Characteristic	N	Aubagio (teriflunomide), N = 800¹	Avonex (interferon beta-1a), N = 530¹	Betaseron (interferon beta-1b), N = 144¹	Extavia (interferon beta-1b), N = 23¹	Gilenya (fingolimod), N = 1423¹	glatiramer acetate, N = 1882¹	Mayzent (siponimod), N = 41¹	Plegridy (pegin-terferon beta-1a), N = 142¹	Rebif (interferon beta-1a), N = 607¹	Tecfidera (dimethyl fumarate), N = 1313¹	Vumerity (diroximol fumarate), N = 42¹	Overall, N = 6947¹
Productivity impacted due to MS	6946
No		763 (95.4%)	519 (97.9%)	142 (98.6%)	23 (100.0%)	1371 (96.3%)	1787 (95.0%)	39 (95.1%)	140 (98.6%)	599 (98.7%)	1283 (97.8%)	41 (97.6%)	6707 (96.6%)
Yes		37 (4.62%)	11 (2.08%)	2 (1.39%)	0 (0%)	52 (3.65%)	95 (5.05%)	2 (4.88%)	2 (1.41%)	8 (1.32%)	29 (2.21%)	1 (2.38%)	239 (3.44%)
Missing		0	0	0	0	0	0	0	0	0	1	0	1
MS-related hospitalization	6946
No		797 (99.6%)	530 (100.0%)	143 (99.3%)	23 (100.0%)	1420 (99.8%)	1873 (99.5%)	41 (100.0%)	142 (100.0%)	607 (100.0%)	1310 (99.8%)	42 (100.0%)	6928 (99.7%)
Yes		3 (0.38%)	0 (0%)	1 (0.69%)	0 (0%)	3 (0.21%)	9 (0.48%)	0 (0%)	0 (0%)	0 (0%)	2 (0.15%)	0 (0%)	18 (0.26%)
Missing		0	0	0	0	0	0	0	0	0	1	0	1
MS-related relapse	6946
No		793 (99.1%)	529 (99.8%)	144 (100.0%)	23 (100.0%)	1413 (99.3%)	1861 (98.9%)	40 (97.6%)	142 (100.0%)	606 (99.8%)	1302 (99.2%)	42 (100.0%)	6895 (99.3%)
Yes		7 (0.88%)	1 (0.19%)	0 (0%)	0 (0%)	10 (0.70%)	21 (1.12%)	1 (2.44%)	0 (0%)	1 (0.16%)	10 (0.76%)	0 (0%)	51 (0.73%)
Missing		0	0	0	0	0	0	0	0	0	1	0	1
¹ n (%)

2.3.3 By productivity PRO

Characteristic	N	No, N = 6707¹	Yes, N = 239¹	Overall, N = 6946¹
Medication prescribed	6946
Aubagio (teriflunomide)		763 (11.4%)	37 (15.5%)	800 (11.5%)
Avonex (interferon beta-1a)		519 (7.74%)	11 (4.60%)	530 (7.63%)
Betaseron (interferon beta-1b)		142 (2.12%)	2 (0.84%)	144 (2.07%)
Extavia (interferon beta-1b)		23 (0.34%)	0 (0%)	23 (0.33%)
Gilenya (fingolimod)		1371 (20.4%)	52 (21.8%)	1423 (20.5%)
glatiramer acetate		1787 (26.6%)	95 (39.7%)	1882 (27.1%)
Mayzent (siponimod)		39 (0.58%)	2 (0.84%)	41 (0.59%)
Plegridy (pegin-terferon beta-1a)		140 (2.09%)	2 (0.84%)	142 (2.04%)
Rebif (interferon beta-1a)		599 (8.93%)	8 (3.35%)	607 (8.74%)
Tecfidera (dimethyl fumarate)		1283 (19.1%)	29 (12.1%)	1312 (18.9%)
Vumerity (diroximol fumarate)		41 (0.61%)	1 (0.42%)	42 (0.60%)
¹ n (%)

2.3.4 By hospitalization PRO

Characteristic	N	No, N = 6928¹	Yes, N = 18¹	Overall, N = 6946¹
Medication prescribed	6946
Aubagio (teriflunomide)		797 (11.5%)	3 (16.7%)	800 (11.5%)
Avonex (interferon beta-1a)		530 (7.65%)	0 (0%)	530 (7.63%)
Betaseron (interferon beta-1b)		143 (2.06%)	1 (5.56%)	144 (2.07%)
Extavia (interferon beta-1b)		23 (0.33%)	0 (0%)	23 (0.33%)
Gilenya (fingolimod)		1420 (20.5%)	3 (16.7%)	1423 (20.5%)
glatiramer acetate		1873 (27.0%)	9 (50.0%)	1882 (27.1%)
Mayzent (siponimod)		41 (0.59%)	0 (0%)	41 (0.59%)
Plegridy (pegin-terferon beta-1a)		142 (2.05%)	0 (0%)	142 (2.04%)
Rebif (interferon beta-1a)		607 (8.76%)	0 (0%)	607 (8.74%)
Tecfidera (dimethyl fumarate)		1310 (18.9%)	2 (11.1%)	1312 (18.9%)
Vumerity (diroximol fumarate)		42 (0.61%)	0 (0%)	42 (0.60%)
¹ n (%)

2.3.5 By relapse PRO

Characteristic	N	No, N = 6895¹	Yes, N = 51¹	Overall, N = 6946¹
Medication prescribed	6946
Aubagio (teriflunomide)		793 (11.5%)	7 (13.7%)	800 (11.5%)
Avonex (interferon beta-1a)		529 (7.67%)	1 (1.96%)	530 (7.63%)
Betaseron (interferon beta-1b)		144 (2.09%)	0 (0%)	144 (2.07%)
Extavia (interferon beta-1b)		23 (0.33%)	0 (0%)	23 (0.33%)
Gilenya (fingolimod)		1413 (20.5%)	10 (19.6%)	1423 (20.5%)
glatiramer acetate		1861 (27.0%)	21 (41.2%)	1882 (27.1%)
Mayzent (siponimod)		40 (0.58%)	1 (1.96%)	41 (0.59%)
Plegridy (pegin-terferon beta-1a)		142 (2.06%)	0 (0%)	142 (2.04%)
Rebif (interferon beta-1a)		606 (8.79%)	1 (1.96%)	607 (8.74%)
Tecfidera (dimethyl fumarate)		1302 (18.9%)	10 (19.6%)	1312 (18.9%)
Vumerity (diroximol fumarate)		42 (0.61%)	0 (0%)	42 (0.60%)
¹ n (%)

3 Patient Reported Outcomes analysis

3.1 Figures

3.2 Productivity impacted due to MS

Characteristic	N	No, N = 824¹	Yes, N = 141¹	p-value²	Overall, N = 965¹
Age at the time of first fill in the study period	965			0.6
Mean (SD)		50.24 (11.05)	50.67 (12.84)		50.30 (11.32)
Median (IQR)		51.00 (42.00 - 58.00)	51.00 (42.00 - 60.00)		51.00 (42.00 - 58.00)
Range		18.00 - 77.00	20.00 - 77.00		18.00 - 77.00
Gender	965			0.3
Female		614 (74.5%)	99 (70.2%)		713 (73.9%)
Male		210 (25.5%)	42 (29.8%)		252 (26.1%)
Insurance	965			<0.001
Commercial		458 (55.6%)	44 (31.2%)		502 (52.0%)
Medicare		281 (34.1%)	68 (48.2%)		349 (36.2%)
Medicaid		85 (10.3%)	29 (20.6%)		114 (11.8%)
Site ID	965			<0.001
Site 1		450 (54.6%)	5 (3.55%)		455 (47.2%)
Site 2		290 (35.2%)	125 (88.7%)		415 (43.0%)
Site 3		38 (4.61%)	11 (7.80%)		49 (5.08%)
Site 4		46 (5.58%)	0 (0%)		46 (4.77%)
PDC	965			0.4
Mean (SD)		0.92 (0.12)	0.93 (0.08)		0.92 (0.11)
Median (IQR)		0.97 (0.90 - 1.00)	0.97 (0.90 - 0.99)		0.97 (0.90 - 0.99)
Range		0.28 - 1.00	0.59 - 1.00		0.28 - 1.00
Administration route	965			0.8
By mouth		418 (50.7%)	69 (48.9%)		487 (50.5%)
Intramuscular injection		59 (7.16%)	8 (5.67%)		67 (6.94%)
Multiple		18 (2.18%)	4 (2.84%)		22 (2.28%)
Subcutaneous injection		329 (39.9%)	60 (42.6%)		389 (40.3%)
Medication prescribed	965
Aubagio (teriflunomide)		99 (12.0%)	21 (14.9%)		120 (12.4%)
Avonex (interferon beta-1a)		59 (7.16%)	8 (5.67%)		67 (6.94%)
Betaseron (interferon beta-1b)		14 (1.70%)	1 (0.71%)		15 (1.55%)
Extavia (interferon beta-1b)		2 (0.24%)	0 (0%)		2 (0.21%)
Gilenya (fingolimod)		153 (18.6%)	27 (19.1%)		180 (18.7%)
glatiramer acetate		239 (29.0%)	50 (35.5%)		289 (29.9%)
Mayzent (siponimod)		8 (0.97%)	1 (0.71%)		9 (0.93%)
Multiple		34 (4.13%)	5 (3.55%)		39 (4.04%)
Plegridy (pegin-terferon beta-1a)		13 (1.58%)	2 (1.42%)		15 (1.55%)
Rebif (interferon beta-1a)		59 (7.16%)	7 (4.96%)		66 (6.84%)
Tecfidera (dimethyl fumarate)		143 (17.4%)	18 (12.8%)		161 (16.7%)
Vumerity (diroximol fumarate)		1 (0.12%)	1 (0.71%)		2 (0.21%)
Number of pharmacist actions	844			<0.001
Mean (SD)		3.47 (2.17)	5.19 (1.81)		3.76 (2.20)
Median (IQR)		3.00 (2.00 - 5.00)	5.00 (4.00 - 6.00)		4.00 (2.00 - 5.00)
Range		1.00 - 13.00	2.00 - 11.00		1.00 - 13.00
Missing		121	0		121
¹ n (%)
² Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test

3.3 MS-related hospitalization

Characteristic	N	No, N = 947¹	Yes, N = 18¹	p-value²	Overall, N = 965¹
Age at the time of first fill in the study period	965			0.7
Mean (SD)		50.28 (11.34)	51.17 (10.87)		50.30 (11.32)
Median (IQR)		51.00 (42.00 - 58.00)	53.50 (46.50 - 56.75)		51.00 (42.00 - 58.00)
Range		18.00 - 77.00	28.00 - 70.00		18.00 - 77.00
Gender	965			0.2
Female		697 (73.6%)	16 (88.9%)		713 (73.9%)
Male		250 (26.4%)	2 (11.1%)		252 (26.1%)
Insurance	965			0.019
Commercial		498 (52.6%)	4 (22.2%)		502 (52.0%)
Medicare		339 (35.8%)	10 (55.6%)		349 (36.2%)
Medicaid		110 (11.6%)	4 (22.2%)		114 (11.8%)
Site ID	965			0.7
Site 1		447 (47.2%)	8 (44.4%)		455 (47.2%)
Site 2		405 (42.8%)	10 (55.6%)		415 (43.0%)
Site 3		49 (5.17%)	0 (0%)		49 (5.08%)
Site 4		46 (4.86%)	0 (0%)		46 (4.77%)
PDC	965			0.012
Mean (SD)		0.92 (0.11)	0.87 (0.11)		0.92 (0.11)
Median (IQR)		0.97 (0.90 - 1.00)	0.88 (0.82 - 0.94)		0.97 (0.90 - 0.99)
Range		0.28 - 1.00	0.59 - 1.00		0.28 - 1.00
Administration route	965			0.4
By mouth		479 (50.6%)	8 (44.4%)		487 (50.5%)
Intramuscular injection		67 (7.07%)	0 (0%)		67 (6.94%)
Multiple		21 (2.22%)	1 (5.56%)		22 (2.28%)
Subcutaneous injection		380 (40.1%)	9 (50.0%)		389 (40.3%)
Medication prescribed	965			0.4
Aubagio (teriflunomide)		117 (12.4%)	3 (16.7%)		120 (12.4%)
Avonex (interferon beta-1a)		67 (7.07%)	0 (0%)		67 (6.94%)
Betaseron (interferon beta-1b)		14 (1.48%)	1 (5.56%)		15 (1.55%)
Extavia (interferon beta-1b)		2 (0.21%)	0 (0%)		2 (0.21%)
Gilenya (fingolimod)		178 (18.8%)	2 (11.1%)		180 (18.7%)
glatiramer acetate		281 (29.7%)	8 (44.4%)		289 (29.9%)
Mayzent (siponimod)		9 (0.95%)	0 (0%)		9 (0.93%)
Multiple		37 (3.91%)	2 (11.1%)		39 (4.04%)
Plegridy (pegin-terferon beta-1a)		15 (1.58%)	0 (0%)		15 (1.55%)
Rebif (interferon beta-1a)		66 (6.97%)	0 (0%)		66 (6.84%)
Tecfidera (dimethyl fumarate)		159 (16.8%)	2 (11.1%)		161 (16.7%)
Vumerity (diroximol fumarate)		2 (0.21%)	0 (0%)		2 (0.21%)
Number of pharmacist actions	844			0.2
Mean (SD)		3.73 (2.18)	4.83 (2.96)		3.76 (2.20)
Median (IQR)		4.00 (2.00 - 5.00)	4.00 (3.00 - 7.00)		4.00 (2.00 - 5.00)
Range		1.00 - 13.00	1.00 - 10.00		1.00 - 13.00
Missing		121	0		121
¹ n (%)
² Wilcoxon rank sum test; Fisher's exact test

3.4 MS-related relapse

Characteristic	N	No, N = 920¹	Yes, N = 45¹	p-value²	Overall, N = 965¹
Age at the time of first fill in the study period	965			0.10
Mean (SD)		50.42 (11.32)	47.93 (11.32)		50.30 (11.32)
Median (IQR)		51.00 (42.75 - 59.00)	49.00 (40.00 - 54.00)		51.00 (42.00 - 58.00)
Range		18.00 - 77.00	26.00 - 77.00		18.00 - 77.00
Gender	965			0.046
Female		674 (73.3%)	39 (86.7%)		713 (73.9%)
Male		246 (26.7%)	6 (13.3%)		252 (26.1%)
Insurance	965			<0.001
Commercial		480 (52.2%)	22 (48.9%)		502 (52.0%)
Medicare		339 (36.8%)	10 (22.2%)		349 (36.2%)
Medicaid		101 (11.0%)	13 (28.9%)		114 (11.8%)
Site ID	965			<0.001
Site 1		447 (48.6%)	8 (17.8%)		455 (47.2%)
Site 2		390 (42.4%)	25 (55.6%)		415 (43.0%)
Site 3		38 (4.13%)	11 (24.4%)		49 (5.08%)
Site 4		45 (4.89%)	1 (2.22%)		46 (4.77%)
PDC	965			0.062
Mean (SD)		0.92 (0.11)	0.90 (0.13)		0.92 (0.11)
Median (IQR)		0.97 (0.90 - 1.00)	0.95 (0.87 - 0.99)		0.97 (0.90 - 0.99)
Range		0.28 - 1.00	0.44 - 1.00		0.28 - 1.00
Administration route	965			0.12
By mouth		462 (50.2%)	25 (55.6%)		487 (50.5%)
Intramuscular injection		66 (7.17%)	1 (2.22%)		67 (6.94%)
Multiple		19 (2.07%)	3 (6.67%)		22 (2.28%)
Subcutaneous injection		373 (40.5%)	16 (35.6%)		389 (40.3%)
Medication prescribed	965
Aubagio (teriflunomide)		115 (12.5%)	5 (11.1%)		120 (12.4%)
Avonex (interferon beta-1a)		66 (7.17%)	1 (2.22%)		67 (6.94%)
Betaseron (interferon beta-1b)		15 (1.63%)	0 (0%)		15 (1.55%)
Extavia (interferon beta-1b)		2 (0.22%)	0 (0%)		2 (0.21%)
Gilenya (fingolimod)		170 (18.5%)	10 (22.2%)		180 (18.7%)
glatiramer acetate		274 (29.8%)	15 (33.3%)		289 (29.9%)
Mayzent (siponimod)		8 (0.87%)	1 (2.22%)		9 (0.93%)
Multiple		36 (3.91%)	3 (6.67%)		39 (4.04%)
Plegridy (pegin-terferon beta-1a)		15 (1.63%)	0 (0%)		15 (1.55%)
Rebif (interferon beta-1a)		65 (7.07%)	1 (2.22%)		66 (6.84%)
Tecfidera (dimethyl fumarate)		152 (16.5%)	9 (20.0%)		161 (16.7%)
Vumerity (diroximol fumarate)		2 (0.22%)	0 (0%)		2 (0.21%)
Number of pharmacist actions	844			<0.001
Mean (SD)		3.70 (2.20)	4.76 (2.13)		3.76 (2.20)
Median (IQR)		4.00 (2.00 - 5.00)	4.00 (4.00 - 6.00)		4.00 (2.00 - 5.00)
Range		1.00 - 13.00	1.00 - 12.00		1.00 - 13.00
Missing		121	0		121
¹ n (%)
² Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test

4 Pharmacist actions and PROs

4.1 Figure

4.2 Productivity

Characteristic	N	No, N = 824	Yes, N = 141	p-value¹	Overall, N = 965
Number of pharmacist actions	844			<0.001
Mean (SD)		3.47 (2.17)	5.19 (1.81)		3.76 (2.20)
Median (IQR)		3.00 (2.00 - 5.00)	5.00 (4.00 - 6.00)		4.00 (2.00 - 5.00)
Range		1.00 - 13.00	2.00 - 11.00		1.00 - 13.00
Missing		121	0		121
General Medication Education	844			<0.001
Mean (SD)		1.60 (1.69)	3.13 (1.64)		1.86 (1.77)
Median (IQR)		1.00 (0.00 - 3.00)	3.00 (2.00 - 4.00)		2.00 (0.00 - 3.00)
Range		0.00 - 9.00	0.00 - 9.00		0.00 - 9.00
Missing		121	0		121
Safety	844			0.013
Mean (SD)		1.40 (1.62)	1.72 (1.64)		1.45 (1.63)
Median (IQR)		1.00 (0.00 - 2.00)	1.00 (0.00 - 3.00)		1.00 (0.00 - 2.00)
Range		0.00 - 9.00	0.00 - 7.00		0.00 - 9.00
Missing		121	0		121
Adherence	844			>0.9
Mean (SD)		0.54 (1.09)	0.67 (1.34)		0.57 (1.14)
Median (IQR)		0.00 (0.00 - 1.00)	0.00 (0.00 - 1.00)		0.00 (0.00 - 1.00)
Range		0.00 - 11.00	0.00 - 9.00		0.00 - 11.00
Missing		121	0		121
Effectiveness	844			>0.9
Mean (SD)		0.18 (0.49)	0.21 (0.60)		0.19 (0.51)
Median (IQR)		0.00 (0.00 - 0.00)	0.00 (0.00 - 0.00)		0.00 (0.00 - 0.00)
Range		0.00 - 4.00	0.00 - 4.00		0.00 - 4.00
Missing		121	0		121
Coordination of care: Non-Financial	844			<0.001
Mean (SD)		0.25 (0.63)	0.06 (0.30)		0.22 (0.59)
Median (IQR)		0.00 (0.00 - 0.00)	0.00 (0.00 - 0.00)		0.00 (0.00 - 0.00)
Range		0.00 - 5.00	0.00 - 2.00		0.00 - 5.00
Missing		121	0		121
Coordination of care: Financial	844			0.025
Mean (SD)		0.09 (0.36)	0.02 (0.14)		0.08 (0.34)
Median (IQR)		0.00 (0.00 - 0.00)	0.00 (0.00 - 0.00)		0.00 (0.00 - 0.00)
Range		0.00 - 3.00	0.00 - 1.00		0.00 - 3.00
Missing		121	0		121
¹ Wilcoxon rank sum test

4.3 Hospitalization

Characteristic	N	No, N = 947	Yes, N = 18	p-value¹	Overall, N = 965
Number of pharmacist actions	844			0.2
Mean (SD)		3.73 (2.18)	4.83 (2.96)		3.76 (2.20)
Median (IQR)		4.00 (2.00 - 5.00)	4.00 (3.00 - 7.00)		4.00 (2.00 - 5.00)
Range		1.00 - 13.00	1.00 - 10.00		1.00 - 13.00
Missing		121	0		121
General Medication Education	844			0.7
Mean (SD)		1.85 (1.75)	2.11 (2.78)		1.86 (1.77)
Median (IQR)		2.00 (0.00 - 3.00)	1.00 (0.00 - 3.75)		2.00 (0.00 - 3.00)
Range		0.00 - 9.00	0.00 - 9.00		0.00 - 9.00
Missing		121	0		121
Safety	844			0.052
Mean (SD)		1.47 (1.64)	0.67 (0.77)		1.45 (1.63)
Median (IQR)		1.00 (0.00 - 2.00)	0.50 (0.00 - 1.00)		1.00 (0.00 - 2.00)
Range		0.00 - 9.00	0.00 - 2.00		0.00 - 9.00
Missing		121	0		121
Adherence	844			0.011
Mean (SD)		0.55 (1.09)	1.50 (2.31)		0.57 (1.14)
Median (IQR)		0.00 (0.00 - 1.00)	1.00 (0.00 - 2.00)		0.00 (0.00 - 1.00)
Range		0.00 - 11.00	0.00 - 9.00		0.00 - 11.00
Missing		121	0		121
Effectiveness	844			0.12
Mean (SD)		0.18 (0.50)	0.39 (0.78)		0.19 (0.51)
Median (IQR)		0.00 (0.00 - 0.00)	0.00 (0.00 - 0.75)		0.00 (0.00 - 0.00)
Range		0.00 - 4.00	0.00 - 3.00		0.00 - 4.00
Missing		121	0		121
Coordination of care: Non-Financial	844			<0.001
Mean (SD)		0.20 (0.57)	0.78 (1.00)		0.22 (0.59)
Median (IQR)		0.00 (0.00 - 0.00)	0.00 (0.00 - 1.75)		0.00 (0.00 - 0.00)
Range		0.00 - 5.00	0.00 - 3.00		0.00 - 5.00
Missing		121	0		121
Coordination of care: Financial	844			0.9
Mean (SD)		0.08 (0.34)	0.06 (0.24)		0.08 (0.34)
Median (IQR)		0.00 (0.00 - 0.00)	0.00 (0.00 - 0.00)		0.00 (0.00 - 0.00)
Range		0.00 - 3.00	0.00 - 1.00		0.00 - 3.00
Missing		121	0		121
¹ Wilcoxon rank sum test

4.4 Relapse

Characteristic	N	No, N = 920	Yes, N = 45	p-value¹	Overall, N = 965
Number of pharmacist actions	844			<0.001
Mean (SD)		3.70 (2.20)	4.76 (2.13)		3.76 (2.20)
Median (IQR)		4.00 (2.00 - 5.00)	4.00 (4.00 - 6.00)		4.00 (2.00 - 5.00)
Range		1.00 - 13.00	1.00 - 12.00		1.00 - 13.00
Missing		121	0		121
General Medication Education	844			0.040
Mean (SD)		1.83 (1.77)	2.33 (1.67)		1.86 (1.77)
Median (IQR)		1.00 (0.00 - 3.00)	2.00 (1.00 - 4.00)		2.00 (0.00 - 3.00)
Range		0.00 - 9.00	0.00 - 6.00		0.00 - 9.00
Missing		121	0		121
Safety	844			<0.001
Mean (SD)		1.41 (1.63)	2.13 (1.53)		1.45 (1.63)
Median (IQR)		1.00 (0.00 - 2.00)	2.00 (1.00 - 3.00)		1.00 (0.00 - 2.00)
Range		0.00 - 9.00	0.00 - 5.00		0.00 - 9.00
Missing		121	0		121
Adherence	844			0.10
Mean (SD)		0.56 (1.14)	0.73 (1.10)		0.57 (1.14)
Median (IQR)		0.00 (0.00 - 1.00)	0.00 (0.00 - 1.00)		0.00 (0.00 - 1.00)
Range		0.00 - 11.00	0.00 - 5.00		0.00 - 11.00
Missing		121	0		121
Effectiveness	844			<0.001
Mean (SD)		0.16 (0.46)	0.71 (0.94)		0.19 (0.51)
Median (IQR)		0.00 (0.00 - 0.00)	0.00 (0.00 - 1.00)		0.00 (0.00 - 0.00)
Range		0.00 - 4.00	0.00 - 4.00		0.00 - 4.00
Missing		121	0		121
Coordination of care: Non-Financial	844			0.5
Mean (SD)		0.22 (0.59)	0.22 (0.47)		0.22 (0.59)
Median (IQR)		0.00 (0.00 - 0.00)	0.00 (0.00 - 0.00)		0.00 (0.00 - 0.00)
Range		0.00 - 5.00	0.00 - 2.00		0.00 - 5.00
Missing		121	0		121
Coordination of care: Financial	844			0.6
Mean (SD)		0.08 (0.34)	0.04 (0.21)		0.08 (0.34)
Median (IQR)		0.00 (0.00 - 0.00)	0.00 (0.00 - 0.00)		0.00 (0.00 - 0.00)
Range		0.00 - 3.00	0.00 - 1.00		0.00 - 3.00
Missing		121	0		121
¹ Wilcoxon rank sum test